PharmaNet and The Research Institute of McGill University Health Center Announce the First Translational Medicine Unit In Canada
PharmaNet Development Group announced that its subsidiary, PharmaNet Canada, Inc. (PharmaNet) and The Research Institute of McGill University Health Center (RI MUHC) have signed a Letter of Intent to jointly form, manage, and operate the first in-hospital translational medicine unit for the conduct of Phase I - IIa clinical studies in Canada.
The state-of-the-art facility will be located at the Montreal General Hospital and is expected to commence operation in 2012. "We are thrilled to announce this joint venture with RI MUHC, a world-renowned research facility," commented Riaz Bandali, President, Early Stage Development, PharmaNet. "The partnership will provide access to PharmaNet's clinical research expertise and the RI MUHC's clinical investigators for the conduct of in-hospital Phase I and IIa studies in patient populations and (aims to) transform how pivotal, proof of concept studies are conducted." Mr. Bandali added,
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
